| Structure |
Catalog |
Product Name |
CAS |
E3 Ligase |
Target |
Inquiry |
 |
BPL-202433 |
(2S,4R)-4-Hydroxy-1-((S)-2-(2-(2-(4-(3-methoxy-4-((4-((2-(methylcarbamoyl)phenyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)phenyl)piperazin-1-yl)ethoxy)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide |
|
VHL |
FAK |
Inquiry |
|
Molecular Weight: 1029.20
Molecular Formula: C52H63F3N10O7S
Description: It is a highly cooperative FAK-degrading PROTAC.
|
 |
BPL-202434 |
(2S,4R)-4-Hydroxy-1-((S)-2-(3-(4-(3-methoxy-4-((4-((2-(methylcarbamoyl)phenyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)phenyl)piperazin-1-yl)propanamido)-3,3-dimethylbutanoyl)-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide |
|
VHL |
FAK |
Inquiry |
|
Molecular Weight: 999.17
Molecular Formula: C51H61F3N10O6S
Description: It is a highly cooperative FAK-degrading PROTAC.
|
![2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-((1-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)-1H-1,2,3-triazol-4-yl)methyl)acetamide](https://resource.bocsci.com/structure/protac2893.gif) |
BPL-202435 |
2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-((1-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)-1H-1,2,3-triazol-4-yl)methyl)acetamide |
|
CRBN |
BRD2
BRD4 |
Inquiry |
|
Molecular Weight: 866.36
Molecular Formula: C41H40ClN11O7S
Description: It is a potent degrader of bromodomain and extra-terminal (BET) proteins.
|
![2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-((1-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamido)butyl)-1H-1,2,3-triazol-4-yl)methyl)acetamide](https://resource.bocsci.com/structure/protac2894.gif) |
BPL-202436 |
2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-((1-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamido)butyl)-1H-1,2,3-triazol-4-yl)methyl)acetamide |
|
CRBN |
BRD2
BRD4 |
Inquiry |
|
Molecular Weight: 865.38
Molecular Formula: C41H41ClN12O6S
Description: It is a potent degrader of bromodomain and extra-terminal (BET) proteins.
|
![2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-((1-(4-(2-(4-(2,6-dioxopiperidin-3-yl)phenoxy)acetamido)butyl)-1H-1,2,3-triazol-4-yl)methyl)acetamide](https://resource.bocsci.com/structure/protac2895.gif) |
BPL-202437 |
2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-((1-(4-(2-(4-(2,6-dioxopiperidin-3-yl)phenoxy)acetamido)butyl)-1H-1,2,3-triazol-4-yl)methyl)acetamide |
|
CRBN |
BRD2
BRD4 |
Inquiry |
|
Molecular Weight: 797.34
Molecular Formula: C39H41ClN10O5S
Description: It is a potent degrader of bromodomain and extra-terminal (BET) proteins.
|
![2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-((1-(4-(2-((4-(2,6-dioxopiperidin-3-yl)phenyl)amino)acetamido)butyl)-1H-1,2,3-triazol-4-yl)methyl)acetamide](https://resource.bocsci.com/structure/protac2896.gif) |
BPL-202438 |
2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-((1-(4-(2-((4-(2,6-dioxopiperidin-3-yl)phenyl)amino)acetamido)butyl)-1H-1,2,3-triazol-4-yl)methyl)acetamide |
|
CRBN |
BRD2
BRD4 |
Inquiry |
|
Molecular Weight: 796.36
Molecular Formula: C39H42ClN11O4S
Description: It is a potent degrader of bromodomain and extra-terminal (BET) proteins.
|
![2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-(2-(4-(2,6-dioxopiperidin-3-yl)phenoxy)acetamido)butyl)acetamide](https://resource.bocsci.com/structure/protac2897.gif) |
BPL-202439 |
2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-(2-(4-(2,6-dioxopiperidin-3-yl)phenoxy)acetamido)butyl)acetamide |
|
CRBN |
BRD2
BRD4 |
Inquiry |
|
Molecular Weight: 716.26
Molecular Formula: C36H38ClN7O5S
Description: It is a potent degrader of bromodomain and extra-terminal (BET) proteins.
|
 |
BPL-202440 |
SJ995973 |
|
CRBN |
BRD4
BRD2 |
Inquiry |
|
Molecular Weight: 730.29
Molecular Formula: C37H40ClN7O5S
Density: 1.4±0.1 g/cm3
Description: SJ995973 is a uniquely potent degrader of bromodomain and extra-terminal (BET) proteins that inhibits the viability of human acute myeloid leukemia MV4-11 cells at low picomolar concentrations (IC50=3 pM; BRD4 DC50=0.87 nM).
|
![2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-(2-(3-(2,6-dioxopiperidin-3-yl)phenoxy)acetamido)butyl)acetamide](https://resource.bocsci.com/structure/protac2899.gif) |
BPL-202441 |
2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-(2-(3-(2,6-dioxopiperidin-3-yl)phenoxy)acetamido)butyl)acetamide |
|
CRBN |
BRD2
BRD4 |
Inquiry |
|
Molecular Weight: 716.26
Molecular Formula: C36H38ClN7O5S
Description: It is a potent degrader of bromodomain and extra-terminal (BET) proteins.
|
![2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(5-(2-(3-(2,6-dioxopiperidin-3-yl)phenoxy)acetamido)pentyl)acetamide](https://resource.bocsci.com/structure/protac2900.gif) |
BPL-202442 |
2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(5-(2-(3-(2,6-dioxopiperidin-3-yl)phenoxy)acetamido)pentyl)acetamide |
|
CRBN |
BRD2
BRD4 |
Inquiry |
|
Molecular Weight: 730.29
Molecular Formula: C37H40ClN7O5S
Description: It is a potent degrader of bromodomain and extra-terminal (BET) proteins.
|
![(2R,4S)-1-((S)-2-(2-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide](https://resource.bocsci.com/structure/2766352-50-3.gif) |
BPL-202443 |
(2R,4S)-1-((S)-2-(2-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
2766352-50-3 |
VHL |
PI3Kalpha |
Inquiry |
|
Molecular Weight: 1017.11
Molecular Formula: C50H46F2N10O8S2
Density: 1.49±0.1 g/cm3
Description: It is a VHL-based PROTAC that targets the degradation of PI3K kinase.
|
![(2R,4S)-1-((S)-2-(3-(2-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzamido)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide](https://resource.bocsci.com/structure/2766352-55-8.gif) |
BPL-202444 |
(2R,4S)-1-((S)-2-(3-(2-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzamido)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
2766352-55-8 |
VHL |
PI3Kalpha |
Inquiry |
|
Molecular Weight: 1088.19
Molecular Formula: C53H51F2N11O9S2
Density: 1.49±0.1 g/cm3
Description: It is a VHL-based PROTAC that targets the degradation of PI3K kinase.
|
![(2R,4S)-1-((S)-2-(4-(2-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzamido)butanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide](https://resource.bocsci.com/structure/2766352-56-9.gif) |
BPL-202445 |
(2R,4S)-1-((S)-2-(4-(2-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzamido)butanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
2766352-56-9 |
VHL |
PI3Kalpha |
Inquiry |
|
Molecular Weight: 1102.22
Molecular Formula: C54H53F2N11O9S2
Density: 1.47±0.1 g/cm3
Description: It is a VHL-based PROTAC that targets the degradation of PI3K kinase.
|
![(2R,4S)-1-((S)-2-(5-(2-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzamido)pentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide](https://resource.bocsci.com/structure/2766352-62-7.gif) |
BPL-202446 |
(2R,4S)-1-((S)-2-(5-(2-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzamido)pentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
2766352-62-7 |
VHL |
PI3Kalpha |
Inquiry |
|
Molecular Weight: 1116.24
Molecular Formula: C55H55F2N11O9S2
Density: 1.46±0.1 g/cm3
Description: It is a VHL-based PROTAC that targets the degradation of PI3K kinase.
|
![(2R,4S)-1-((S)-2-(6-(2-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzamido)hexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide](https://resource.bocsci.com/structure/2766352-63-8.gif) |
BPL-202447 |
(2R,4S)-1-((S)-2-(6-(2-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzamido)hexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
2766352-63-8 |
VHL |
PI3Kalpha |
Inquiry |
|
Molecular Weight: 1130.27
Molecular Formula: C56H57F2N11O9S2
Density: 1.45±0.1 g/cm3
Description: It is a VHL-based PROTAC that targets the degradation of PI3K kinase.
|
![(2R,4S)-1-((S)-2-(7-(2-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzamido)heptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide](https://resource.bocsci.com/structure/2766352-64-9.gif) |
BPL-202448 |
(2R,4S)-1-((S)-2-(7-(2-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzamido)heptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
2766352-64-9 |
VHL |
PI3Kalpha |
Inquiry |
|
Molecular Weight: 1144.28
Molecular Formula: C57H59F2N11O9S2
Density: 1.44±0.1 g/cm3
Description: It is a VHL-based PROTAC that targets the degradation of PI3K kinase.
|
![(2R,4S)-1-((S)-2-(8-(2-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzamido)octanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide](https://resource.bocsci.com/structure/2766352-65-0.gif) |
BPL-202449 |
(2R,4S)-1-((S)-2-(8-(2-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzamido)octanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
2766352-65-0 |
VHL |
PI3Kalpha |
Inquiry |
|
Molecular Weight: 1158.32
Molecular Formula: C58H61F2N11O9S2
Density: 1.43±0.1 g/cm3
Description: It is a VHL-based PROTAC that targets the degradation of PI3K kinase.
|
![(2R,4S)-1-((S)-2-(2-(2-(2-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzamido)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide](https://resource.bocsci.com/structure/2766352-70-7.gif) |
BPL-202450 |
(2R,4S)-1-((S)-2-(2-(2-(2-(5-(6-(5-((2,4-Difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)benzamido)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
2766352-70-7 |
VHL |
PI3Kalpha |
Inquiry |
|
Molecular Weight: 1118.21
Molecular Formula: C54H53F2N11O10S2
Density: 1.48±0.1 g/cm3
Description: It is a VHL-based PROTAC that targets the degradation of PI3K kinase.
|
![(2R,4S)-1-((S)-12-(tert-Butyl)-1-(2-(5-(6-(5-((2,4-difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)phenyl)-1,10-dioxo-5,8-dioxa-2,11-diazatridecan-13-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide](https://resource.bocsci.com/structure/2766352-71-8.gif) |
BPL-202451 |
(2R,4S)-1-((S)-12-(tert-Butyl)-1-(2-(5-(6-(5-((2,4-difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)phenyl)-1,10-dioxo-5,8-dioxa-2,11-diazatridecan-13-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
2766352-71-8 |
VHL |
PI3Kalpha |
Inquiry |
|
Molecular Weight: 1162.27
Molecular Formula: C56H57F2N11O11S2
Density: 1.47±0.1 g/cm3
Description: It is a VHL-based PROTAC that targets the degradation of PI3K kinase.
|
![(2R,4S)-1-((S)-15-(tert-Butyl)-1-(2-(5-(6-(5-((2,4-difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)phenyl)-1,13-dioxo-5,8,11-trioxa-2,14-diazahexadecan-16-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide](https://resource.bocsci.com/structure/2766352-79-6.gif) |
BPL-202452 |
(2R,4S)-1-((S)-15-(tert-Butyl)-1-(2-(5-(6-(5-((2,4-difluorophenyl)sulfonamido)-6-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-3-yl)-1,3,4-oxadiazol-2-yl)phenyl)-1,13-dioxo-5,8,11-trioxa-2,14-diazahexadecan-16-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
2766352-79-6 |
VHL |
PI3Kalpha |
Inquiry |
|
Molecular Weight: 1206.32
Molecular Formula: C58H61F2N11O12S2
Density: 1.45±0.1 g/cm3
Description: It is a VHL-based PROTAC that targets the degradation of PI3K kinase.
|
